# National Medical Products Administration **Entity class:** Government regulatory agency **Domain:** Medical Device and Drug Regulation / China **Doc Type:** Institution Node **Maturity:** Developing **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] ## Definition **The National Medical Products Administration (NMPA) is China's national regulator for drugs, medical devices and cosmetics, administered under the State Administration for Market Regulation.** It replaced the China Food and Drug Administration in the 2018 government restructuring. For the neurotechnology corpus it matters as the regulator that issued the first market approval for an implanted brain-computer interface: [[wiki/Neuracle|Neuracle]]'s NEO, a Class III device, on 13 March 2026. ## Role in brain-computer interfaces - **First implanted-BCI approval.** NEO was approved for hand-motor function in adults with cervical spinal-cord injury after 36 procedures across a feasibility study and an 11-hospital multicenter trial. - **Special review for innovative devices.** Shanghai reported three invasive BCI products from its enterprises in the NMPA's special review procedure for innovative medical devices at the time of the NEO approval. - **Co-author of national industrial policy.** The NMPA is one of the seven issuing bodies of the [[wiki/China BCI Industry Implementation Opinions|Implementation Opinions on Promoting Innovation and Development of the Brain-Computer Interface Industry]] (30 July 2025). Building the regulator into the industrial plan from the start is how China compresses the interval between capability and authorization. - **Pricing and reimbursement adjacency.** Separate from the NMPA, the National Healthcare Security Administration issued BCI pricing guidelines in April 2025 and reportedly assigned NEO an insurance code within about twelve days of approval (single-source report). ## Forward Capability A regulator that approves first sets the evidentiary template others are measured against. With an implanted BCI on its register and a national plan targeting clinical and commercial use by 2027, the NMPA holds a precedent the FDA has yet to set. Where the FDA's Breakthrough Device program reorders a queue, China's coordinated plan joins the regulator, the industrial ministries and the payer in one policy instrument. ## Open Questions - The NMPA registration certificate for NEO: exact indication text, classification rationale and post-market obligations. - Whether the NMPA publishes a BCI-specific technical review guideline, and its relation to ISO/IEC JTC 1/SC 43 standards. - The timing of a second invasive-BCI registration; NeuroXess was in a year-long trial at the time of the NEO approval. ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 and tier recommendations come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0010 — Strongly indicated.** Breakthrough Device designation functions as a scheduling instrument: it does not lower the evidentiary bar, it reorders the queue. In a field where first classification sets the template for everything behind it, queue position converts directly into standards authorship. - **INF-0055 — Strongly indicated.** The first PMA for a permanently implanted BCI creates the classification template every subsequent device is measured against. Regulatory precedent is a form of standards authorship, and it is being competed for by a small number of firms on a two-to-three-year horizon. - **INF-0367 — Strongly indicated.** Clinical programs migrate toward jurisdictions with faster pathways, which relocates the evidence base for frontier interventions. Reading where trials are run is the most reliable indicator of where a capability will first become ordinary. - **INF-0494 — Analytic.** The interval between a capability existing and its public authorization is set by politics, liability, and market readiness rather than by technical maturity. Measuring the lag in adjacent fields gives a defensible estimate for this one. ## Relationships - **approved:** [[wiki/Neuracle|Neuracle]] NEO — first market approval of an implanted BCI, 13 March 2026. - **co_issuer_of:** [[wiki/China BCI Industry Implementation Opinions|China BCI Industry Implementation Opinions]] (30 July 2025). - **national_program:** [[wiki/China Brain Project|China Brain Project]]. - **regulatory_peer:** [[wiki/FDA Breakthrough Device|FDA Breakthrough Device]] (U.S. scheduling instrument) and the EU notified-body route used by [[wiki/PRIMA Retinal Implant|PRIMA Retinal Implant]]. - **policy_peer:** [[wiki/Cyberspace Administration of China|Cyberspace Administration of China]] (data governance for connected devices). - **ecosystem:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[wiki/Brain-Computer Interfaces|Brain-Computer Interfaces]] · [[collections/Neurotech|Neurotech]]. ## Sources - [China grants world's first market approval for invasive BCI product — Xinhua, 14 March 2026](https://english.news.cn/20260314/fab8a8e69f004c74a6b40e2d6ae5bc54/c.html) - [Clinical Translation of Brain-Computer Interface in China — arXiv 2607.07185, July 2026](https://arxiv.org/pdf/2607.07185) - [MERICS brief on China's BCI implementation opinions, 2025](https://merics.org/index%2Ephp/de/merics-briefs/manufacturing-metrology-brain-machine-tech-tackling-talent-shortages) As of 23 October 2026.